Click (NASDAQ:CLIK) Stock Price Down 17.4% – Here’s Why

Click Holdings Limited (NASDAQ:CLIK) fell 17.4% during trading on Tuesday . The company traded as low as $1.51 and last traded at $1.52. 866,407 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 2,662,997 shares. The stock had previously closed at $1.84.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Click in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Click Price Performance

The stock has a fifty day moving average price of $2.13 and a two-hundred day moving average price of $3.69.

Click (NASDAQ:CLIK) last released its earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Click stock. Renaissance Technologies LLC acquired a new stake in shares of Click Holdings Limited (NASDAQ:CLIK) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click at the end of the most recent reporting period.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.